Population pharmacokinetics of gentamicin and dosing optimization for infants.
The aim of this study was to characterize and validate the population pharmacokinetics of gentamicin in infants and to determine the influences of clinically relevant covariates to explain the inter- and intraindividual variabilities associated with this drug. Infants receiving intravenous gentamicin and with routine therapeutic drug monitoring were consecutively enrolled in the study. Plasma concentration and time data were retrospectively collected from 208 infants (1 to 24 months old) of the Hospital Universitario Severo Ochoa (Spain), of whom 44% were males (mean age [± standard deviation], 5.8 ± 4.8 months; mean body weight, 6.4 ± 2.2 kg). Data analysis was performed with NONMEM 7.2. One- and two-compartment open models were analyzed to estimate the gentamicin population parameters and the influences of several covariates. External validation was carried out in another population of 55 infants. The behavior of gentamicin in infants exhibits two-compartment pharmacokinetics, with total body weight being the covariate that mainly influences central volume (Vc) and clearance (CL); this parameter was also related to creatinine clearance. Both parameters are age related and different from those reported for neonatal populations. On the basis of clinical presentation and diagnosis, a once-daily dosage regimen of 7 mg/kg of body weight every 24 h is proposed for intravenous gentamicin, followed by therapeutic drug monitoring in order to avoid toxicity and ensure efficacy with minimal blood sampling. Gentamicin pharmacokinetics and disposition were accurately characterized in this pediatric population (infants), with the parameters obtained being different from those reported for neonates and children. These differences should be considered in the dosing and therapeutic monitoring of this antibiotic.
Departamento de Farmacia, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico susanna.garibay@gmail.com.
Susanna E
SE
Medellín-Garibay
Servicio de Farmacia, Hospital Universitario Severo Ochoa, Leganés, Spain.
Aída
A
Rueda-Naharro
Servicio de Farmacia, Hospital Universitario Severo Ochoa, Leganés, Spain.
Silvia
S
Peña-Cabia
Servicio de Farmacia, Hospital Universitario Severo Ochoa, Leganés, Spain.
Benito
B
García
Departamento de Farmacia, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
Silvia
S
Romano-Moreno
Departamento de Farmacia y Tecnología Farmacéutica, Universidad Complutense de Madrid, Plaza de Ramón y Cajal, Ciudad Universitaria, Madrid, Spain.
Emilia
E
Barcia
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D054316:Biomarkers, Pharmacological / Q000097:blood*; D001835:Body Weight; D002675:Child, Preschool; D003404:Creatinine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D012189:Retrospective Studies
D000900:Anti-Bacterial Agents; D054316:Biomarkers, Pharmacological; D005839:Gentamicins; D003404:Creatinine